Cash & Equivalents
Gilead Sciences Cash & Equivalents increased by 3.2% to $7.56B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 24.3%, from $9.99B to $7.56B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 4.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.89B | $4.36B | $5.34B | $4.30B | $4.74B | $4.70B | $5.41B | $4.94B | $5.70B | $5.71B | $6.09B | $4.72B | $2.77B | $5.04B | $9.99B | $7.93B | $5.14B | $7.33B | $7.56B |
| QoQ Change | — | -10.9% | +22.4% | -19.5% | +10.3% | -0.8% | +15.2% | -8.8% | +15.6% | +0.0% | +6.7% | -22.5% | -41.2% | +81.7% | +98.4% | -20.7% | -35.1% | +42.5% | +3.2% |
| YoY Change | — | — | — | — | -3.1% | +7.7% | +1.4% | +14.9% | +20.4% | +21.4% | +12.4% | -4.4% | -51.4% | -11.7% | +64.2% | +68.0% | +85.6% | +45.5% | -24.3% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's cash & equivalents?
- Gilead Sciences (GILD) reported cash & equivalents of $7.56B in Q4 2025.
- How has Gilead Sciences's cash & equivalents changed year-over-year?
- Gilead Sciences's cash & equivalents decreased by 24.3% year-over-year, from $9.99B to $7.56B.
- What is the long-term trend for Gilead Sciences's cash & equivalents?
- Over 5 years (2020 to 2025), Gilead Sciences's cash & equivalents has grown at a 4.8% compound annual growth rate (CAGR), from $6.00B to $7.56B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.